Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Foscan receives orphan drug designation in U.S.; MAA accepted in E.U.

Nov. 17, 1999

Pharmaceutical agents useful as vitronectin antagonists and methods of use

Nov. 17, 1999

Kinase inhibitors developed at Boehringer Ingelheim as potential anticancer agents

Nov. 17, 1999

Ontogen completes phase I multidose oral study of MDR compound

Nov. 17, 1999

Preclinical data highlight Xcytrin's anticancer activity and novel mechanism of action

Nov. 17, 1999

New data reported on thalidomide for several cancer indications

Nov. 17, 1999

OHSU study will evaluate vitamin D in patients with recurring prostate cancer

Nov. 16, 1999

Kotobuki presents new sulfonamide MMP inhibitors

Nov. 15, 1999

Antisense compounds from Isis target human cancer-associated mdm2

Nov. 15, 1999

Photogen teams up with Akorn to advance development of PH-10

Nov. 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...